These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 17917277)

  • 1. Inhibitory effects of ginsenosides and their hydrolyzed metabolites on daunorubicin transport in KB-C2 cells.
    Kitagawa S; Takahashi T; Nabekura T; Tachikawa E; Hasegawa H
    Biol Pharm Bull; 2007 Oct; 30(10):1979-81. PubMed ID: 17917277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered activity of MDR-reversing agents on KB3-1 cells transfected with Gly(185)-->Val human P-glycoprotein.
    Watanabe T; Uchiyama N; Roninson IB; Cohen D; Atadja P
    Int J Oncol; 2000 Sep; 17(3):579-86. PubMed ID: 10938401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monensin and verapamil do not alter intracellular localisation of daunorubicin in multidrug resistant human KB cells.
    Wood DJ; Rumsby MG; Warr JR
    Cancer Lett; 1996 Nov; 108(1):41-7. PubMed ID: 8950207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of cyclosporin and azidopine binding are associated with altered ATPase activity by a mutant P-glycoprotein with deleted phe(335).
    Chen KG; Lacayo NJ; Durán GE; Cohen D; Sikic BI
    Mol Pharmacol; 2000 Apr; 57(4):769-77. PubMed ID: 10727524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity relationship and mechanism of flavonoids on the inhibitory activity of P-glycoprotein (P-gp)-mediated transport of rhodamine123 and daunorubicin in P-gp overexpressed human mouth epidermal carcinoma (KB/MDR) cells.
    Fang Y; Liang F; Xia M; Cao W; Pan S; Wu T; Xu X
    Food Chem Toxicol; 2021 Sep; 155():112381. PubMed ID: 34217736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Actin disruption inhibits endosomal traffic of P-glycoprotein-EGFP and resistance to daunorubicin accumulation.
    Fu D; Roufogalis BD
    Am J Physiol Cell Physiol; 2007 Apr; 292(4):C1543-52. PubMed ID: 17122416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterisation of multidrug-resistant Ehrlich ascites tumour cells selected in vivo for resistance to etoposide.
    Nielsen D; Maare C; Eriksen J; Litman T; Friche E; Skovsgaard T
    Biochem Pharmacol; 2000 Aug; 60(3):353-61. PubMed ID: 10856430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of drug accumulation in P-glycoprotein-expressing and MRP-expressing human leukaemia cells.
    Davey MW; Hargrave RM; Davey RA
    Leuk Res; 1996 Aug; 20(8):657-64. PubMed ID: 8913319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction.
    Ax W; Soldan M; Koch L; Maser E
    Biochem Pharmacol; 2000 Feb; 59(3):293-300. PubMed ID: 10609558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport.
    Katoh M; Nakajima M; Yamazaki H; Yokoi T
    Eur J Pharm Sci; 2001 Feb; 12(4):505-13. PubMed ID: 11231118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterisation of non-P-glycoprotein multidrug-resistant Ehrlich ascites tumour cells selected for resistance to mitoxantrone.
    Nielsen D; Eriksen J; Maare C; Litman T; Kjaersgaard E; Plesner T; Friche E; Skovsgaard T
    Biochem Pharmacol; 2000 Aug; 60(3):363-70. PubMed ID: 10856431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of P-glycoprotein function by tannic acid and pentagalloylglucose.
    Kitagawa S; Nabekura T; Nakamura Y; Takahashi T; Kashiwada Y
    J Pharm Pharmacol; 2007 Jul; 59(7):965-9. PubMed ID: 17637191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of P-glycoprotein-mediated multidrug resistance by protopanaxatriol ginsenosides from Korean red ginseng.
    Choi CH; Kang G; Min YD
    Planta Med; 2003 Mar; 69(3):235-40. PubMed ID: 12677527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influx of daunorubicin in multidrug resistant Ehrlich ascites tumour cells: correlation to expression of P-glycoprotein and efflux. Influence of verapamil.
    Nielsen D; Maare C; Skovsgaard T
    Biochem Pharmacol; 1995 Aug; 50(4):443-50. PubMed ID: 7646548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of P-glycoprotein function by tea catechins in KB-C2 cells.
    Kitagawa S; Nabekura T; Kamiyama S
    J Pharm Pharmacol; 2004 Aug; 56(8):1001-5. PubMed ID: 15285844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of P-glycoprotein to bunitrolol efflux across blood-brain barrier.
    Matsuzaki J; Yamamoto C; Miyama T; Takanaga H; Matsuo H; Ishizuka H; Kawahara Y; Kuwano M; Naito M; Tsuruo T; Sawada Y
    Biopharm Drug Dispos; 1999 Mar; 20(2):85-90. PubMed ID: 10206323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of P-glycoprotein and multidrug resistance protein 1 by dietary phytochemicals.
    Nabekura T; Yamaki T; Ueno K; Kitagawa S
    Cancer Chemother Pharmacol; 2008 Oct; 62(5):867-73. PubMed ID: 18204840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclosporin A has low potency as a calcineurin inhibitor in cells expressing high levels of P-glycoprotein.
    Fakata KL; Elmquist WF; Swanson SA; Vorce RL; Prince C; Stemmer PM
    Life Sci; 1998; 62(26):2441-8. PubMed ID: 9651111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel energy dependent mechanism reducing daunorubicin accumulation in acute myeloid leukemia.
    Hedley DW; Xie SX; Minden MD; Choi CH; Chen H; Ling V
    Leukemia; 1997 Jan; 11(1):48-53. PubMed ID: 9001418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular uptake and antiproliferative effects of therapeutic concentrations of idarubicin or daunorubicin and their alcohol metabolites, with or without cyclosporin A, in MDR1+ human leukemic cells.
    Chiodini B; Bassan R; Barbui T
    Leuk Lymphoma; 1999 May; 33(5-6):485-97. PubMed ID: 10342576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.